Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 406 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Twice Weekly Clear all

Conditions: Psoriasis
Interventions: Etanercept, Placebo injections; Biological · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Irvine, California • Winston-Salem, North Carolina • Seattle, Washington

Conditions: Cocaine Abuse, Cocaine-Related Disorders
Interventions: Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: placebo, Exenatide LAR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 7
States / cities: Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more

Conditions: Anorexia Nervosa
Interventions: RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 22 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo; Drug · Behavioral
Lead sponsor: Michael Aman; Other
Eligibility: 6 Years to 12 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more

Conditions: Candidiasis
Interventions: fluconazole, placebo; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 2 Days to 5 Days
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 33
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more

Conditions: Constipation Chronic Idiopathic
Interventions: Vibrant capsule, Placebo capsule; Device
Lead sponsor: Vibrant Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Westminster, California • Cutler Bay, Florida

Conditions: Diabetic Peripheral Neuropathy
Interventions: Mazisotine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: HIV-1-infection
Interventions: Saline, Lefitolimod, 3BNC117 and 10-1074; Drug
Lead sponsor: University of Aarhus; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pelvic Organ Prolapse
Interventions: Vaginal estrogen, Placebo; Drug
Lead sponsor: Pamela Moalli; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Overweight, Obesity, Weight Management, Appetite Control
Interventions: MN Nutra GeLiPthin-1™ Dietary Supplement, Placebo; Dietary Supplement
Lead sponsor: MNnutra; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Rialto, California • Sacramento, California • Miami, Florida + 8 more

Conditions: Obsessive-compulsive Disorder
Interventions: Cognitive-behavioral therapy, D-cycloserine, Placebo pill; Behavioral · Drug
Lead sponsor: University of South Florida; Other
Eligibility: 8 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Cognitive remediation training, Nicotine polacrilex lozenge; Behavioral · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: CMV
Interventions: Brincidofovir, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 39
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 25 more

Conditions: Cutaneous T-Cell Lymphoma
Interventions: SGX301 (synthetic hypericin), Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Psoriasis
Interventions: Placebo, 50 mg etanercept, 80 mg ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more

Conditions: Arthritis, Reactive, Reiter Disease
Interventions: Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Tampa, Florida • New Orleans, Louisiana

Conditions: Fragile X Syndrome
Interventions: AFQ056, Placebo, Language Intervention; Drug · Other
Lead sponsor: Elizabeth Berry-Kravis; Other
Eligibility: 32 Months to 6 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 14
States / cities: Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: inhaled carbon monoxide, Oxygen; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 4 more

Conditions: Osteoarthritis, Knee
Interventions: Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly; Drug
Lead sponsor: Paradigm Biopharmaceuticals USA (INC); Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 29
States / cities: Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more

Conditions: Multiple Sclerosis
Interventions: Speed of Processing Training (SPT), Placebo Control; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 59 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Systemic Sclerosis
Interventions: Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

Medications for Stopping Cocaine Dependence and Preventing Relapse

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Effects of Anorexia Nervosa on Peak Bone Mass

Treatment of Severe Childhood Aggression (The TOSCA Study)

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Vibrant Capsule vs. Placebo for Patient Suffering From Constipation

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse

A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

AFQ056 for Language Learning in Children With FXS

Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Speed of Processing Training to Improve Cognition in Multiple Sclerosis

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis